A Zepbound lawsuit is a personal-injury claim alleging the drug's manufacturer, Eli Lilly, failed to adequately warn patients about serious side effects — chiefly severe gastrointestinal injury and, in a separate set of cases, sudden vision loss. Zepbound is Lilly's brand name for tirzepatide, a GLP-1 receptor agonist approved for weight loss. These claims are not scattered individual disputes. Federal courts have grouped thousands of them into coordinated proceedings, and state courts in New Jersey have done the same, because the underlying allegations and evidence overlap closely enough that one process handles pretrial issues for everyone.
Official resources:
- Read the official notice from Uscourts — Use this primary source to verify the official announcement.
- Read the official notice from Uscourts — Use this primary source to verify the official announcement.
Table of Contents
- What the Lawsuits Actually Allege
- Does the Zepbound Label Already Warn About These Risks?
- Why Diagnosis Is a Central Fight in the Gastrointestinal Cases
- Where the Litigation Stands and What Comes Next
- Who These Claims Potentially Affect
- Frequently Asked Questions
What the Lawsuits Actually Allege
The core claim is a failure-to-warn theory: that Lilly knew or should have known tirzepatide carried risks of gastroparesis (a stomach-paralysis condition), ileus, and intestinal obstruction, and did not give patients or doctors adequate warning. Plaintiffs in the federal MDL centralized in the Eastern District of Pennsylvania make this argument against both Lilly, for tirzepatide drugs Zepbound and Mounjaro, and Novo Nordisk, for its own GLP-1 products. A second, separate wave of cases alleges a different injury entirely: NAION, or nonarteritic anterior ischemic optic neuropathy, a sudden and often permanent form of vision loss. The Judicial Panel on Multidistrict Litigation centralized these claims into a distinct proceeding, MDL No.
3163, also assigned to a judge in the Eastern District of Pennsylvania. Gastrointestinal injury and vision-loss claims are litigated on separate tracks because they involve different alleged mechanisms and different medical evidence. A third, unrelated legal front has nothing to do with physical injury. A September 2025 ERISA class action in the Southern District of New York accuses CVS Caremark of breaching its fiduciary duty to plan members by dropping Zepbound from its largest commercial formulary in favor of Wegovy after negotiating a lower net price with Novo Nordisk, according to Bloomberg Law's reporting. CVS has called the two drugs "clinically similar products" and said the suits lack merit.
Does the Zepbound Label Already Warn About These Risks?
Yes, to a point, and the scope of that existing warning is central to the litigation. The FDA-approved label, revised in February 2026, states that tirzepatide "has been associated with gastrointestinal adverse reactions, sometimes severe," and specifies that Zepbound "is not recommended in patients with severe gastroparesis". Lilly's own medical-information page confirms the drug has not been studied in patients with severe gastroparesis, which is why it carries that restriction, as described on Lilly Medical's website.
The label also carries a boxed warning — the FDA's strongest warning category — stating that tirzepatide caused thyroid C-cell tumors in rodent studies, that it remains unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, and that the drug is contraindicated for anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2, per the same FDA-hosted prescribing information. Plaintiffs argue these warnings came too late or remain incomplete relative to what Lilly knew. Lilly disputes the premise that its warnings were inadequate, and it is contesting how gastroparesis claims get proven in the first place, which is the subject of the next section.
Why Diagnosis Is a Central Fight in the Gastrointestinal Cases
Eli Lilly has asked the judge presiding over MDL 3094 to require objective diagnostic testing before any plaintiff can establish a gastroparesis diagnosis. Lilly argues that without such testing, the condition is misdiagnosed in as many as 80% of cases, according to reporting by the Indianapolis Business Journal on the MDL filings.
Plaintiffs' counsel, by contrast, claim hundreds to thousands of linked gastroparesis cases exist. This dispute matters because it will likely shape which cases can proceed to bellwether trials — the early test trials used in mass litigation to gauge how juries respond to the evidence before larger settlement talks begin. A plaintiff whose diagnosis rests on symptoms alone, without imaging or motility testing, may face a tougher path if Lilly's position prevails.
Where the Litigation Stands and What Comes Next
As of the Judicial Panel's July 1, 2026 count, 3,848 cases were pending in the gastrointestinal-injury MDL (No. 3094). The related vision-loss proceeding, MDL 3163, had roughly 216 actions pending as of September 1, 2026, according to reporting by IBTimes UK citing JPML statistics.
Neither MDL had a global settlement or a scheduled bellwether trial date as of the courts' public dockets through September 2026. Outside the federal system, the New Jersey Supreme Court has designated two separate multicounty litigations in state court for GLP-1 drug claims: one covering gastrointestinal injuries and one covering NAION vision loss, spanning Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound, according to an official notice from the New Jersey Courts. A plaintiff's options generally depend on where they live and where they were treated:.
- Federal gastrointestinal claims consolidate in MDL 3094 (E.D. Pa.)
- Federal NAION vision-loss claims consolidate in MDL 3163 (E.D. Pa.)
- New Jersey state-court claims proceed through one of the two multicounty litigations
- ERISA-based formulary disputes, like the CVS Caremark case, proceed separately from any injury claim
Who These Claims Potentially Affect
The gastrointestinal claims center on patients who took tirzepatide and later experienced gastroparesis, ileus, or intestinal obstruction or pseudo-obstruction severe enough to require medical treatment. The vision-loss claims involve patients who developed NAION, a condition that can cause sudden, permanent loss of vision in one eye, after starting a GLP-1 drug.
Patients with no personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 fall outside the boxed-warning contraindication, but that does not resolve the separate failure-to-warn allegations tied to gastrointestinal injury. Anyone evaluating a potential claim should expect that documented medical treatment — not just reported symptoms — will matter given Lilly's position on diagnostic testing described above.
Frequently Asked Questions
Are Zepbound lawsuits and Ozempic lawsuits the same case?
No. Ozempic and Wegovy use a different active ingredient (semaglutide) than Zepbound and Mounjaro (tirzepatide), but claims against both drug families have been organized into related proceedings, including New Jersey's state-court litigations covering both drug types.
Has Eli Lilly settled any Zepbound injury claims?
No global settlement had been reached and no bellwether trial date had been set in either federal MDL as of the courts' public dockets through September 2026.
Is the CVS Caremark lawsuit about drug safety?
No. That case is an ERISA fiduciary-duty claim over CVS Caremark's formulary decision to favor Wegovy over Zepbound after a pricing deal with Novo Nordisk; it does not allege either drug caused injury.